1. Home
  2. QFIN vs TLX Comparison

QFIN vs TLX Comparison

Compare QFIN & TLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • QFIN
  • TLX
  • Stock Information
  • Founded
  • QFIN 2016
  • TLX 2015
  • Country
  • QFIN China
  • TLX Australia
  • Employees
  • QFIN N/A
  • TLX N/A
  • Industry
  • QFIN Finance: Consumer Services
  • TLX Biotechnology: Pharmaceutical Preparations
  • Sector
  • QFIN Finance
  • TLX Health Care
  • Exchange
  • QFIN Nasdaq
  • TLX Nasdaq
  • Market Cap
  • QFIN 5.0B
  • TLX 5.7B
  • IPO Year
  • QFIN 2018
  • TLX N/A
  • Fundamental
  • Price
  • QFIN $42.74
  • TLX $16.42
  • Analyst Decision
  • QFIN Strong Buy
  • TLX Strong Buy
  • Analyst Count
  • QFIN 2
  • TLX 2
  • Target Price
  • QFIN $45.10
  • TLX $22.00
  • AVG Volume (30 Days)
  • QFIN 1.1M
  • TLX 40.7K
  • Earning Date
  • QFIN 08-12-2025
  • TLX 01-01-0001
  • Dividend Yield
  • QFIN 3.28%
  • TLX N/A
  • EPS Growth
  • QFIN 68.59
  • TLX 798.14
  • EPS
  • QFIN 6.45
  • TLX 0.09
  • Revenue
  • QFIN $2,439,629,299.00
  • TLX $484,687,790.00
  • Revenue This Year
  • QFIN $10.94
  • TLX N/A
  • Revenue Next Year
  • QFIN $6.54
  • TLX N/A
  • P/E Ratio
  • QFIN $6.67
  • TLX $178.10
  • Revenue Growth
  • QFIN 5.10
  • TLX 55.85
  • 52 Week Low
  • QFIN $18.13
  • TLX $13.61
  • 52 Week High
  • QFIN $48.94
  • TLX $30.36
  • Technical
  • Relative Strength Index (RSI)
  • QFIN 48.02
  • TLX N/A
  • Support Level
  • QFIN $42.38
  • TLX N/A
  • Resistance Level
  • QFIN $46.18
  • TLX N/A
  • Average True Range (ATR)
  • QFIN 1.36
  • TLX 0.00
  • MACD
  • QFIN -0.04
  • TLX 0.00
  • Stochastic Oscillator
  • QFIN 35.94
  • TLX 0.00

About QFIN Qifu Technology Inc.

Qifu Technology Inc is a Credit-Tech platform in China. It provides credit services more accessible and personalized to consumers and SMEs through Credit-Tech services to financial institutions, whereby it deploys its technology solutions to help financial institutions identify the diversified needs of consumers and SMEs, effectively access prospective borrowers that are creditworthy through multi-channels, enhance credit assessment on prospective borrowers, and manage credit risks and improve collection strategies and efficiency, among others.

About TLX Telix Pharmaceuticals Limited American Depositary Shares

Telix develops radiopharmaceuticals to manage cancer. Radiopharmaceuticals are radioisotopes bound to molecules that can target specific cells. At low doses, these drugs can bind to specific cancer cells with radiation, and then positron emission tomography imaging can accurately visualize tumors. At high doses, these drugs can selectively target and treat tumors with radiation, known as radioligand therapy. Radiopharmaceuticals are usually injected into the bloodstream. Telix has a pipeline of potential radiopharmaceuticals but currently earns most of its revenue from US sales of Illuccix, largely used as an imaging agent to visualize the spread of prostate cancer.

Share on Social Networks: